BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35100709)

  • 1. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational characteristics of bone metastasis of lung cancer.
    Huang X; Shi X; Huang D; Li B; Lin N; Pan W; Yan X; Li H; Hao Q; Ye Z
    Ann Palliat Med; 2021 Aug; 10(8):8818-8826. PubMed ID: 34488370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic landscape and prognosis of patients with
    Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
    Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The co-mutation of
    Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
    J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Sharpnack MF; Cho JH; Johnson TS; Otterson GA; Shields PG; Huang K; Carbone DP; He K
    Lung Cancer; 2020 Aug; 146():36-41. PubMed ID: 32505734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.
    Li L; Chen C; Liu C; Niu L; Pan C
    Ann Transl Med; 2022 Feb; 10(4):214. PubMed ID: 35280376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma.
    Feng A; Li Y; Li G; Wang Y; Wen Q; Yang Z; Tian K; Lv H; Guo L; Zhang S; Liu X; Jiang D
    Front Oncol; 2022; 12():908759. PubMed ID: 35912232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer.
    Chen B; Li R; Zhang J; Xu L; Jiang F
    Pathol Oncol Res; 2022; 28():1610020. PubMed ID: 35783357
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
    Wang H; Chen S; Meng D; Wu C; Zhu J; Jiang M; Ning J; Wu S; Wu L; Li J; Chen B; Zhao S; Li W; Yu J; Fang Q; Zhu J; Zhao W; He Y; Zhou C
    Onco Targets Ther; 2021; 14():2953-2965. PubMed ID: 33976553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in
    Xiang L; Fu X; Wang X; Li W; Zheng X; Nan K; Tian T
    Front Oncol; 2020; 10():559896. PubMed ID: 33072585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
    Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
    Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
    Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
    Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma.
    Cai X; Chen Z; Deng M; Li Z; Wu Q; Wei J; Dai C; Wang G; Luo C
    Ann Transl Med; 2020 Sep; 8(18):1176. PubMed ID: 33241025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.